Combination by Using an Automatic Turbidimetric System
|
|
- Charleen Curtis
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 196, p /6/6997-$2./ Copyright 196, American Society for Microbiology Vol. 29, No. 6 In Vitro Evaluation of Various Antifungal Agents Alone and in Combination by Using an Automatic Turbidimetric System Combined with Viable Count Determinations P. VAN DER AUWERA,* A. M. CEUPPENS, C. HEYMANS, AND F. MEUNIER Service de Medecine Interne et Laboratoire d'investigation Clinique H. J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'universite Libre de Bruxelles, 1 Brussels, Belgium Received 31 October 195/Accepted 26 February 196 A new method combining automatic turbidimetry and sequential viable count determinations was developed to evaluate the in vitro activity of various antifungal agents alone and in combination against three clinical isolates of Candida spp. (two Candida albicans and one C. tropicalis) at two inocula (15 and 16 CFU/ml). Specific parameters were derived from the time-kill curves: the maximal rate of killing, the lowest biomass, and the overnight biomass. Their intra-assay and between-assay reproducibilities were high, with respective standard deviations of. and.25 to 1. log CFU/ml. Amphotericin B alone showed a linear relationship between rate of killing or lowest biomass and the log of concentration from.3 to mg/liter that was similar for the three strains tested. 5-Fluorocytosine (flucytosine) alone showed a dose-related reduction of overnight biomass for concentrations up to mg/liter with no further increase at higher concentrations for one strain of C. albicans and a paradoxical decrease for one strain of C. tropicalis. Ketoconazole alone was found to be only fungistatic with no increased activity at concentrations up to 16 mg/liter. Amphotericin B plus flucytosine interacted synergistically in 6 to 6% of the combinations tested against C. tropicalis depending on the initial inoculum. Indifference was observed for the two strains of C. albicans. Amphotericin B or flucytosine plus ketoconazole was usually indifferent against the three tested strains. There is a lack of standardization of the methods used to evaluate in vitro antifungal activity. The results are highly dependent upon the medium, inoculum size, and temperature (3, 21, 23). Recently, a multicenter study (2) showed that the broth dilution procedure recommended by Shadomy and Espinel-Ingroff (22) was reproducible in each laboratory, whereas interlaboratory precision was poor. Published studies (7, ) that use turbidimetry measurement are encouraging, and there is a suggestion that this technique be proposed to standardize the in vitro susceptibility testing of yeasts. Moreover, the in vitro evaluation of combinations of various compounds also shows a lack of standardization as far as the definition of synergism, indifference, or antagonism is concerned. Therefore, comparison of the results obtained by different investigators is often difficult. Nevertheless, the value of antifungal combinations has been widely studied to improve the prognosis of life-threatening infections and has been recently reviewed (19). The aim of this study was to develop a reliable method to evaluate systematically the in vitro activity of various antifungal drugs, alone or in combinations, against Candida species, using standardized parameters derived from continuous optical density measurements (turbidimetric system) and viable count determinations (time-kill curves). MATERIALS AND METHODS All tests were performed in a Bonet-Maury biophotometer (ISA-Biologie, Paris, France) with six quartz cuvettes of ml each. Constant mixing was provided in each cuvette by a magnetic barrel moved by a magnetic stirrer. Optical transmission through each cuvette was automatically measured every 2 min and recorded on a chart (percent transmission versus time in hours). * Corresponding author. 997 The following clinical isolates were studied: two strains of Candida albicans (strains 1 and 2) and one strain of C. tropicalis. These three strains were isolated from fungemic cancer patients hospitalized at the Institut Jules Bordet. Stock cultures were maintained on Sabouraud slants (Difco Laboratories, Belgium) in screw-capped tubes at room temperature. Fresh Sabouraud agar plates were inoculated from the stock cultures and incubated for 2 h at 3 C. Four colonies were transferred in a tube containing 1 ml of yeast nitrogen base (YNB) broth (Difco, Belgium) plus 1% glucose and homogenized. This suspension was used to inoculate the test cuvette with 1 or 1 drops, according to the target inoculum chosen for each experiment. The optical transmission was set at 1% and incubation was started at 3 C. The antifungal agents were added at a transmission of 5%, which corresponded to the exponential phase of growth, which occurred usually after 1 to 2 h of incubation, considered time zero. A sample of.1 ml was obtained from the first cuvette for viable count determination prior to the addition of antifungal agent to the initial inoculum. At this time the cuvettes inoculated with 1 drop had reached 2 x 15 CFU/ml (range, 1 x 15 to 3 x 15 CFU/ml), and those inoculated with 1 drops had reached 2 x 16 CFU/ml (1 x 16 to 3.2 x 16). Each hour during the first 5 h and after overnight incubation, a.1-ml sample was obtained from each cuvette for viable count determination. This was done by sequential 1-fold dilutions in distilled water and by plating each dilution on Sabouraud agar plates with a calibrated loop (.1 ml). The medium used in the cuvettes was YNB broth (Difco) plus 1% glucose and.15% asparagine. The following compounds were tested: amphotericin B deoxycholate (Fungizone; Squibb, Belgium), final concentration of.3 to mg/liter; 5-fluorocytosine (flucytosine; Roche, Belgium);.25 to 32 mg/liter; ketoconazole (Janssen Pharmaceutica, Belgium), 1 to 16 mg/liter. All possible Downloaded from on November 3, 21 by guest
2 99 VAN DER AUWERA ET AL. ANTIMICROB. AGENTS CHEMOTHER. PH -J -i a IL. a TIME ( hrs ] TIME ( hrs) FIG. 1. Killing curves of C. albicans strain 1 exposed to amphotericin B, flucytosine, and their combination in buffered and unbuffered YNB. The broken lines indicate the ph measured in the cuvettes without antifungal agent. Symbols: O, amphotericin B (1 mg/liter); *, amphotericin B ( mg/liter);, flucytosine (16 mg/liter); A, amphotericin B (1 mg/liter) and flucytosine (16 mg/liter); A, amphotericin B ( mg/liter) and flucytosine (16 mg/liter). combinations of these drugs in pairs were also tested within the range of concentrations previously mentioned, using the two previously described inocula (2 x 15 and 2 x 16 CFU/ml). For each experiment studying the in vitro activity of a single agent, five cuvettes contained various concentrations of the tested agent and one cuvette was the without antifungal agent. For evaluation of the in vitro activity of combinations, one cuvette was the drug-free, one cuvette contained a fixed concentration of drug A, two cuvettes contained two different concentrations of drug B, and two cuvettes contained the two different combinations of drug A with drug B. Preparation of stock solutions. Stock solutions were prepared according to the recommendations of the manufacturer and stored at - C until used. Amphotericin B was dissolved in distilled water at a concentration of 5, mg/liter, flucytosine was obtained already diluted as intravenous infusion containers and further diluted to obtain a concentration of 1, mg/liter, and ketoconazole was dissolved in dimethyl sulfoxide at a concentration of 5, mg/liter. Time-kill curves. The following parameters were derived from the killing curves: the maximal rate of killing (RK), expressed in log CFU per milliliter per hour, was defined as the highest reduction in viable count per hour; the lowest biomass reached (LB), expressed in log CFU per milliliter, was defined as the highest reduction in the viable count during the experiment and was obtained by subtracting the lowest viable count observed from the initial inoculum size; the overnight biomass (OB), expressed in log CFU per milliliter, was defined as the viable count observed after overnight incubation. Synergy was reached when one of the following criteria was achieved: the maximal RK of the combination was 2.5 U. log CFU/ml per h greater than the corresponding value of the most active drug used alone; the LB obtained with the combination was lower (21 log CFU/ml) than the corresponding LB obtained with the most active drug used alone; the OB obtained with the combination was lower. (-1 log CFU/ml) than the corresponding OB obtained with the most active drug used alone. Antagonism was defined as a similar quantitative decrease in activity measured by the same parameters. All other situations were considered indifference. Reproducibility. The intra-assay reproducibility of the viable count determination was assessed by sampling 2 times a cuvette prepared as described above to reach an inoculum of 2 x 15 CFU of C. albicans strain 1 per ml. For each combination tested, cuvettes containing each antifungal agent at every tested concentration were included simultaneously. The results for all concentrations of each agent tested alone (2 experiments) were submitted to statistical analysis, and this constituted the between-assay reproducibility. Twelve combinations were tested in duplicate, including six different combinations of amphotericin B plus flucytosine, three combinations of amphotericin B plus ketoconazole, and three combinations of flucytosine plus ketoconazole. Most combinations were tested in unbuffered YNB, but six different combinations of amphotericin B plus flucytosine were also tested simultaneously in buffered YNB (23) to evaluate the ph effect. RESULTS Reproducibility. The study of intra-assay reproducibility of the viable count determination gave the following results: the mean inoculum was 2.5 x 15 CFU/ml, the range was 1.6 Downloaded from on November 3, 21 by guest
3 VOL. 29, 196 C.E a IA F I ~~~~~5 1 t - 5 t 1 Optical curves _ ~~~~~~~~~~~~~~.6 AMPHOTERICIN D7 U ~6 FLUORO( CYTOS INE cc~~~~~~~~~c u 3t 6 -~~~~=,., cntrol ~~~KETOC CONAZOLE Time ~~~~~~~~~~~~~~~~~~~~ IN VITRO EVALUATION OF ANTIFUNGAL AGENTS 999 Time-Kill curves cont rol B A - E (hour) FIG. 2. In vitro activities of amphotericin B, flucytosine (5-fluorocytosine), and ketoconazole in liquid YNB against C. albicans 1, measured by continuous turbidimetry recording or sequential viable count determinations. Concentrations are in milligrams per liter. Arrow indicates addition of the antifungal agent. to.3 x 15 CFU/ml, and the standard deviation was. x 15 CFU/ml. The between-assay reproducibility (over 2 experiments) of the measure of the maximal RK varied with the concentration of amphotericin B: at.6 mg/liter the standard deviation was.35 log CFU/ml per h whereas at mg/liter it ranged from. to 1.1 log CFU/ml per h. The between-assay reproducibility of the measure of the LB also depended on the concentration of amphotericin B and varied from. to 1. log CFU/ml per h. The between-assay reproducibility of the measure of the OB for flucytosine varied from.25 to.6 log CFU/ml. Twelve combinations tested in duplicate provided a similar pattern of interactions between each pair of the tested antifungal combinations when synergy, indifference, and antagonism were defined by the previously described criteria. No discordance occurred in the interpretation of the combinations tested in buffered or unbuffered YNB. Figure 1 shows such a comparison between buffered and unbuffered YNB and the ph evolution in the cuvette without antifungal agents. Activity of a single agent. The effects observed with amphotericin B, flucytosine, or ketoconazole alone are summarized in Fig. 2 for C. albicans strain 1. The results obtained for the two other strains were similar (Fig. 3 and ). Amphotericin B. For amphotericin B, the latency to the first optical effect was about.5 h and did not change when the drug's concentration was increased. The optical curves showed a typical decrease in optical density accompanying a rapid killing of the yeast cells as shown on the corresponding time-kill curves. Both the optical and killing curves indicated Time ( hour)3 a dose-related activity when measured by either the latency to regrowth (in hours) derived from the optical curve or the parameters derived from the killing curve (maximal RK, LB, or OB). This relationship between dose and activity was also confirmed for the three tested strains by plotting the maximal RK and the LB against amphotericin B log concentration (Fig. 5). The linear correlations obtained within the range of tested concentrations were highly statistically significant (Pearson coefficient of linear correlation,.95; P <.1). Inoculum dependency was low: a decrease of.5 log CFU/ml per h occurred in the maximal RK for each tested concentration by increasing the inoculum from 2 x 15 to 2 x 16 CFU/ml, resulting in a loss of about.5 log CFU/ml in the LB. Flucytosine. The types of curves observed for flucytosine alone were different from those obtained for amphotericin B alone (Fig. 2 and 3). As can be seen on the optical curves, the growth was similarly affected by the various concentrations of flucytosine tested. The delay to regrowth appeared to depend on the concentration of flucytosine. The killing curves (Fig. 2 and 3) demonstrated a fungicidal effect occurring later than the one observed with amphotericin B. Figure 6 shows the relationship between the LB and the concentration of flucytosine within the range of.12 to 6 mg/liter. The LB was linearly dependent on the concentration of flucytosine only for low concentrations (< mg/liter). At higher concentrations ( to 6 mg/liter) the LB was no longer affected by the concentration of flucytosine for the strain of C. tropicalis or was paradoxically affected for the two other strains of C. albicans. Inoculum dependency was higher *1 Downloaded from on November 3, 21 by guest
4 1 VAN DER AUWERA ET AL. ANTIMICROB. AGENTS CHEMOTHER. Optical curves Time - Kill curves 5t _ = ~~~~~~6 E" / r ~~5FLUOROQYTOSINE ~~~~~~~~~~~~~~~~~~~~~~~c -5 KE TOCONAZOLE w Time (hourr) Time (hourj FIG. 3. In vitro activities of amphotericin B, flucytosine (5-fluorocytosine), and ketoconazole in liquid YNB against C. tropicalis, measured by continuous turbidimetry recording or sequential viable count determinations. Concentrations are in milligrams per liter. Arrow indicates addition of the antifungal agent. than that observed for amphotericin B since a loss of 1 log CFU/ml occurred in the LB by increasing the inoculum from 2 x 15 to 2 x 16 CFU/ml. Ketoconazole. Optical and killing curves failed to demonstrate an effect of ketoconazole at high inoculum for all tested concentrations (Fig. 2 and 3). However, ketoconazole affected the optical and killing curves at the low inoculum - c._ E I E N.- Of F U3._._ ~~~3 2~~~~3 tested (15 CFU/ml) (Fig. 7). Similar results were obtained for the three tested strains. Combinations of antifungal drugs. (i) Amphotericin B plus flucytosine. By using the three parameters derived from the killing curves, synergy was observed by at least one criterion in 5.o% (22 of ) (inoculum, 2 x 16 CFU/ml) and 6.% (29 of ) (inoculum, 2 x 1 CFU/ml) of the combinations -J U. i7,l _ 6 16 Downloaded from on November 3, 21 by guest Time ( hour ) Time (hour) FIG.. In vitro activity of amphotericin B in liquid YNB against C. albicans 2, measured by continuous turbidimetry recording or sequential viable count determinations. Concentrations are in milligrams per liter. Arrow indicates addition of the antifungal agent.
5 VOL. 29, 196 IN VITRO EVALUATION OF ANTIFUNGAL AGENTS 11 5r ---A Candida albicans 1 ---Candida albicans 2 -- Candida tropicalis x E 3 IL D U. C- L. x E U-1 U n 7-1 m -J 2 1 o (mg/ I) Downloaded from -5 L FIG. 5. Correlation between the concentration of amphotericin B and its activity measured by the maximal RK and the LB: mean + standard deviation for 2 experiments for each strain tested. RK and LB were derived from the time-kill curves. Initial inoculum, 2 x 16 CFU/ml in YNB. against C. tropicalis. Antagonism was observed in 16.6% ( of ) of the combinations (inoculum, 2 x 15 CFU/ml) and in 25% (12 of ) of the combinations tested at high inoculum (2 x 16 CFU/ml). Antagonism was mostly observed when the maximal RK was considered: 16.6% ( of ) and 2.% (1 of ), respectively, for low and high inocula. Antagonism was less often demonstrated when evaluated by the other parameters: respectively,.1% (2 of ) and.3% ( of ) for the OB, 2% (1 of ) and 6.2% (3 of ) for the LB. The effect of the combination of amphotericin B and flucytosine was related to the characteristic effect on the killing curve of each drug tested alone. Within the combination, amphotericin B mainly affected the RK (which occurred early), while flucytosine mainly affected the OB. The interval of concentration of amphotericin B, for which synergy was more likely to occur, was narrow; synergy was seldom observed for combinations containing low (<.25 mg/liter) or high (>1 mg/liter) concentrations of amphotericin B (Fig. ). (ii) Other combinations. The combination of amphotericin B with ketoconazole was usually indifferent; however, antagonism could be observed whenever the amphotericin B concentration was..25 mg/liter (Fig. ). Similarly, the combination of flucytosine and ketoconazole was usually indifferent; however, antagonism could also be observed whenever the ketoconazole concentration was >2 mg/liter. This was observed for the three strains tested. DISCUSSION The in vitro study of antifungal activity remains a major area of controversy, and discordance among several investigators must be related to the methodology. The use of an automated turbidimetric system has marked advantages over conventional methods performed either in broth (micro- or macromethod) or in agar, for the following reasons: of the growth phase (the antifungal agents can be added during either exponential growth or stationary phase); of the inoculum by simultaneous measure of the viable count; constant shaking to provide homogeneous contact between yeast cells and active agents, permitting a homogeneous sampling during the incubation. In a multicuvette system it is also possible to compare simultaneously different concentrations of such agent or combinations of drugs. in strictly led conditions. The volume of broth ( ml) used here allowed us to study a large population of cells. The reproducibility of the system was high as exemplified on November 3, 21 by guest
6 12 VAN DER AUWERA ET AL. ANTIMICROB. AGENTS CHEMOTHER. U- CL) -i A- Candida albicans I A- --ACandida tropicalis I~~~~~~~~~~~~~,I. a. T~~~~~~~~~~~~~ le FLUOROCYTOSINE CONCENTRATION (mg/i) FIG. 6. Dose-activity relationship of flucytosine on the LB. This parameter was derived from the killing curves. Each point represents the mean of 2 experiments. Bars represent standard deviation. 5 Fluorocytosine, Flucytosine. by the small standard deviations shown in Fig. 5 and 6. The cutoff values in the maximal RK, the LB, and the OB between indifference and synergy or antagonism were chosen according to the intra-assay reproducibility of the viable count determination and the between-assay reproducibilty of these parameters measured in cuvettes evaluating a single agent. The cutoff value for the LB and OB used here were smaller than what is usually recommended for the investigation of antibiotic combinations against bacteria; however, - OF -1i -2L 1 the conventional 2-log difference has not been supported by similar reproducibility studies with yeasts. Amphotericin B showed a dose-activity relationship. The linearity of the relation should permit use of the checkerboard method to assess the interaction between amphotericin B and other drugs, providing that these drugs show the same property. However, whether efficacy of amphotericin B correlates with the dose remains controversial (1, 5, 16, 2, 26). Failures and relapses are numerous despite amphotericin B therapy. Preliminary data from our patients suggest a lack of fungicidal activity in the sera of patients treated with conventional regimens of amphotericin B (F. Meunier-Carpentier, A. Coune, J. P. Sculier, N. Collette, C. Heymans, C. Brassinne, C. Laduron, and J: Klastersky, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 35, p. 16, 195). The major problem in transposing an in vitro generated dose-activity relationship to an in vivo situation is the toxicity of amphotericin B, precluding its use at higher doses. Recently, it has been suggested that incorporation of amphotericin B into liposomes might be one way of administering amphotericin B at high doses without increasing its side effects (13; Meunier- Carpentier et al., 25th ICAAC), and this approach, using unilamellar liposomes, has already shown an enhanced in vitro fungicidal activity of amphotericin B against yeasts (F. Meunier-Carpentier, J. Taterman, C. Brassinne, C. Laduron, and A. Coune, Program Abstr. 2th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 13, p. 273, 19). The correlation between in vitro susceptibility in broth of C. albicans isolates to flucytosine and the in vivo response to therapy was confirmed in an experimental murine candidiasis (25). In the present study, flucytosine was found to be much less rapidly fungicidal than amphotericin B; it was nevertheless possible to construct a dose-activity relationship. For one strain (C. albicans 1) a maximal effect was reached at mg/liter followed by a plateau even when the concentration was raised to 6 mg/liter; the other strain (C. tropicalis) showed a paradoxical effect. In this situation, the checkerboard methodology to assess the activity of combinations would be inappropriate. Ketoconazole showed only fungistatic activity, and no dose-activity relationship could be generated in our automated turbidimetric system. The system we have used here provides the opportunity to evaluate quantitatively drug-activity alone or in combina- Optical curves Time_-Kill curves E [ Downloaded from on November 3, 21 by guest i a I.- 5i 1L KE TOCONAZOLE I- a. * c u S 'U l " O Time ( hour ) Time (hour) FIG. 7. In vitro activity of ketoconazole against C. albicans 1 at a low initial inoculum (1 CFU/ml).
7 VOL. 29, 196 IN VITRO EVALUATION OF ANTIFUNGAL AGENTS AMPHOTE RICIN B - 5FLUOROCYTOSINE AMPHOTE RIC IN B - KETOCONAZOLE E 6 IL U o 5 C c i 3 a A.25 5SFC I AO.25+ 5FC Time (hour) FIG.. In vitro activity of the combination of amphotericin B (A) and flucytosine (5-fluorocytosine; 5 FC) (left), and amphotericin B and ketoconazole (Ke) (right) against C. albicans 1. tions. The use of parameters such as the maximal RK or the LB permits the study of intra- and interassay reproducibility, which is not the case with other methods. The interaction between amphotericin B and flucytosine was found complex, since certain combinations were synergistic while others were antagonistic or indifferent. Hamilton and Elliott (1) have shown an in vitro and in vivo synergistic interaction between amphotericin B and flucytosine against Cryptococcus neoformans. Medoff et al (17, 1) have found a synergistic interaction between amphotericin B and flucytosine against one strain each of C. albicans and C. tropicalis and a single concentration of amphotericin B (.2 and.7 mg/liter, respectively) and flucytosine (1 mg/liter). It was suggested that amphotericin B increases the penetration of flucytosine through the fungal cytoplasmic membrane. The combination of amphotericin B and ketoconazole was occasionally synergistic when amphotericin B was in the sub-mic range of concentration. However, for higher concentrations of amphotericin B, antagonism was usually observed. Ketoconazole (1, 27) is an inhibitor of sterol synthesis, and amphotericin B activity is probably mediated by interaction with membrane ergosterol (, 11, 26). On this basis, antagonism was to be expected. Odds (2), using different methods and original definitions for MIC, synergy, indifference, additivity, and antagonism, reported that amphotericin B plus ketoconazole affected synergistically of 11 strains while affecting antagonistically 1 of 11 strains. Unfortunately, the concentrations of each antifungal agent at which synergy could occur were not provided. We have previously shown that the combination of amphotericin B with rifampin was only occasionally synergistic (2), using the same methodology. Synergy was only documented for one of three studied strains, and the occurrence of synergy significantly depended on the ratio of concentrations of amphotericin B and rifampin. Synergy was more likely to I+ Ke occur in Sabouraud than in YNB medium. It is thought that amphotericin B increases the permeability of the fungal cell to rifampin, allowing it to inhibit the DNA-primed RNA polymerase (12, 15). However, in two animal models of disseminated candidiasis, rifampin did not enhance the cure rate obtained with amphotericin B (6, 9). Therefore, the clinical relevance of these in vitro observations as well as the use of this combination in the treatment of patients remain controversial. Although the approach used here may be more cumbersome than the traditional methods, its ultimate value should be determined by its correlation with experimental models of yeast infections in animals and clinical outcome in patients with severe Candida spp. infections. ACKNOWLEDGMENT F. Meunier is a senior research assistant of the Fonds National de la Recherche Scientifique, Belgium. LITERATURE CITED 1. Bayer, A. S., J. E. Edwards, Jr., and L. B. Guze Experimental intraabdominal candidiasis in rabbits: therapy with low-total-dose intravenous amphotericin B. Antimicrob. Agents Chemother. 19: Calhoun, D. L., G. D. Roberts, J. N. Gagliani, J. E. Bennett, D. S. Feingold, J. Jorgensen, G. S. Kobayashi, and S. Shadomy Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. Antimicrob. Agents Chemother. 23: Chmell, H., and D. Louria. 19. Antifungal antibiotics: mechanism of action, resistance, susceptibility testing, and assays of activity in biological fluids, p In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore.. Drutz, D. J. 19. Newer antifungal agents and their use, Downloaded from on November 3, 21 by guest
8 1 VAN DER AUWERA ET AL. including an update on amphotericin B and flucytosine, p In J. S. Remington and M. Swartz (ed.), Current clinical topics in infectious disease, vol. 3. McGraw-Hill Book Co., New York. 5. Drutz, D. J., A. Spickard, D. E. Rogers, and M. G. Koenig Treatment of disseminated mycotic infections. A new approach to amphotericin B therapy. Am. J. Med. 5: Ernst, J. D., M. Rusnak, and M. A. Sande Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. Rev. Infect. Dis. 5(Suppl. 3):S Galgiani, J. N., and D. A. Stevens Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob. Agents Chemother. 1: Galgiani, J. N., and D. A. Stevens Turbidimetric study of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob. Agents Chemother. 13: Graybill, J. R., and J. Ahrens Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev. Infect. Dis. 5(Suppl. 3):S Hamilton, J. D., and D. M. Elliott Combined activity of amphotericin B & 5 Fluoro-cytosine against Cryptococcus neoformans in vitro and in vivo in mice. J. Infect. Dis. 131: Hammond, S. M., P. A. Lambert, and B. N. Klinger. 19. The mode of action of polyene antibiotics, induced potassium leakage in Candida albicans. J. Gen. Microbiol. 117: Kobayashi, G. S., G. Medoff, D. Schlessinger, C. N. Kwan, and W. F. Musser Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science 177: Lopez-Berestein, G., V. Fainstein, R. Hopfer, K. Mehta, M. P. Sullivan, M. Keating, M. G. Rosenblum, R. Mehta, M. Lena, E. M. Hersh, J. Reuben, R. L. Juliano, and G. Bodey Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151: Marriott, M. S. 19. Inhibition of sterol biosynthesis in Candida albicans by imidazole containing antifungals. J. Gen. Microbiol. 117: Medoff, G Antifungal action of rifampin. Rev. Infect. Dis. 5(Suppl. 3):S Medoff, G., J. Brajtburg, J. R. Little, D. Schlessinger, and G. S. Kobayashi. 19. Antifungal therapy, p In P. Verhoef, P. K. Peterson, and P. G. Quie (ed.), Infections in the immunocompromised host-pathogenesis, prevention and therapy. ANTIMICROB. AGENTS CHEMOTHER. Elsevier/North-Holland Biomedical Press, Amsterdam. 17. Medoff, G., M. Comfort, and G. Kobayashi Synergistic action of amphotericin B and 5-fluorocytosine against yeast like organisms. Proc. Soc. Exp. Biol. Med. 13: Medoff, G., G. S. Kobayashi, C. N. Kwan, D. Schlessinger, and P. Venkov Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc. Natl. Acad. Sci. USA 69: Meunier-Carpentier, F Combination of antifungal agents for systemic mycotic diseases, pp In J. Klastersky and M. J. Staquet (ed.), Combination therapy in the compromized host. Raven Press, New York. 2. Odds, F. C Interaction among amphotericin B, 5- fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob. Agents Chemother. 22: Shadomy, S In vitro studies with 5-fluorocytosine. Appl. Microbiol. 17: Shadomy, S., and A. Espinel-Ingroff. 19. Susceptibility testing with antifungal drugs, p In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and J. P. Truant (ed.), Manual of clinical microbiology, 3rd ed. American Society for Microbiology, Washington, D.C. 23. Shadomy, S., A. Espinell-Ingroff, and R. Cartwright Laboratory studies with antifungal agents: susceptibility tests and bioassays, p In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and S. Shadomy (ed.), Manual of clinical microbiology, th ed. American Society for Microbiology, Washington, D.C. 2. Solomkin, J. S., A. Flohr, and R. L. Simmons Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann. Surg. 195: Stiller, R. L., J. E. Bennett, H. J. Scholer, M. Wall, A. Polak, and D. A. Stevens Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J. Infect. Dis. 17: Utz, J. P Chemotherapy of systemic mycoses. Med. Clin. N. Am. 66: Van den Bossche, M., G. Willemsens, W. Cools, F. Cornelissen, W. S. Lauwers, and J. M. Van Cutsem. 19. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob. Agents Chemother. 17: Van der Auwera, P., and F. Meunier-Carpentier In vitro study of amphotericin B plus rifampin on Candida species, p In C. S. F. Easmon and H. Gaya (ed.), Proceedings of the 2nd International Symposium on Infections in the Immunocompromized Host. Academic Press, Inc. (London), Ltd., London. Downloaded from on November 3, 21 by guest
5-Fluorocytosine resistance in clinical isolates of cryptococcus neoformans
Med. J. Malaysia Vol. 44 No. 3 September 1989 5-Fluorocytosine resistance in clinical isolates of cryptococcus neoformans C.S. Chin, B Se (Hons) Y.M. Cheong, MBBS, M Se Bacteriology Division Institute
More informationEffect of Ketoconazole and Amphotericin B on Encapsulated and Non-Encapsulated Strains of Cryptococcus neoformans
ANTIMICROBIAL AGNTS AND CHMOTHRAPY, Dec. 983, p. 8-8 Vol. 24, No. "484/83/28-$2./ Copyright C 983, American Society for Microbiology ffect of Ketoconazole and Amphotericin B on ncapsulated and Non-ncapsulated
More informationAction of Antifungal Imidazoles on Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1982, p. 47 474 66-484/82/947-4$2./ Copyright 1982, American Society for Microbiology Vol. 22, No. 3 Action of Antifungal Imidazoles on Staphylococcus aureus
More informationThe Effect of Cilofungin (LY ) in Combination with Amphotericin B
rnycoses 32 (3) 151-157. accepted/angenommen: October 3,1988. 0 Grosse Verlag Berlin 1989 The Effect of Cilofungin (LY 121019) in Combination with Amphotericin B or Flucytosine Against Candida Species
More informationIn Vitro Studies with R 51,211 (Itraconazole)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1984, p. 5-9 Vol. 26, No. 1 0066-4804/84/070005-05$02.00/0 Copyright 1984, American Society for Microbiology In Vitro Studies with R 51,211 (Itraconazole) ANA
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationEvaluation of in Vitro Antifungal Activity of Ketoconazole and Griseofulvin
Evaluation of in Vitro Antifungal Activity of Ketoconazole and Griseofulvin Abstract Pages with reference to book, From 230 To 234 Taj B. Uppal ( Department of Pathology Khyber Medical College, Peshawar.
More informationAntifungal susceptibility testing using the E test: comparison with the broth macrodilution technique
Journal of Antimicrobial Chemotherapy (996) 7, 65-7 Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique Sharon C. A. Chen, Maryann L. O'Donnell, Suzannah
More informationCandida albicans. with liposomal amphotericin B bearing antibody to. Treatment of a murine model of systemic candidiasis
J. Med. Microbiol. - Vol. 30 (1989), 193-197 0 1989 The Pathological Society of Great Britain and Ireland 0022-26 1 5/89/003(M 193/$10.00 Treatment of a murine model of systemic candidiasis with liposomal
More informationReceived 24 September 2001/Returned for modification 2 February 2002/Accepted 31 May 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2002, p. 2982 2989 Vol. 46, No. 9 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.9.2982 2989.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationdida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans
dida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans Key words: Susceptibility test, IC99, miconazole, fluconazole, itraconazole, Micro-dilution method, 96-multiwell plate Table 1. Cunteffis
More informationMolecular Basis for the Selective Toxicity of Amphotericin B
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1974, p. 377-382 Copyright 0 1974 American Society for Microbiology Vol. 5, No. 4 Printed in U.S.A. Molecular Basis for the Selective Toxicity of Amphotericin
More informationIntracellular Growth of Candida albicans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1991, p. 2275-2281 0066-4804/91/112275-07$02.00/0 Copyright 1991, American Society for Microbiology Vol. 35, No. 11 Effects of Amphotericin B and Fluconazole
More informationIn Vitro Evaluation of Combination of Fluconazole and Flucytosine against Cryptococcus neoformans var. neoformans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1691 1695 Vol. 39, No. 8 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology In Vitro Evaluation of Combination of Fluconazole and
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationANTIMYCOTIC DRUGS Modes of Action
ANTIMYCOTIC DRUGS Modes of Action Prapasarakul Nuvee, D.V.M., Ph.D. Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University 1 What drugs act as antifungal agents?
More informationTherapeutic Evaluation of Free and Liposome-Encapsulated Amphotericin B in the Treatment of Systemic Candidiasis in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1989, p. 1544-1548 0066-4804/89/091544-05$02.00/0 Copyright 1989, American Society for Microbiology Vol. 33, No. 9 Therapeutic Evaluation of Free and Liposome-Encapsulated
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationSynergism of Fosfomycin-Ampicillin and Fosfomycin-
ANTIMICROBiAL AGENTS AND CHEMoTHERAPY, May 1978, p. 75-79 66-484/78/13-75$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 5 Printed in U.S.A. Synergism of Fosfomycin-Ampicillin and Fosfomycin-
More informationDetermination of MIC & MBC
1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationRifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationCombination Treatment of Invasive Fungal Infections
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2005, p. 163 194 Vol. 18, No. 1 0893-8512/05/$08.00 0 doi:10.1128/cmr.18.1.163 194.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Combination
More informationComparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin B Methyl Ester
ANTIMICROBiAL AGENTS AND CHEMOTHERAY, Jan. 975, P. 58-63 Copyright 0 975 American Society for Microbiology Vol. 7, No. Printed in U.S.A. Comparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin
More informationEffect of Severity of Meningitis on Fungicidal Activity of Flucytosine Combined with Fluconazole in a Murine Model of Cryptococcal Meningitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1997, p. 1589 1593 Vol. 41, No. 7 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Effect of Severity of Meningitis on Fungicidal Activity
More informationInteractions between Triazoles and Amphotericin B against Cryptococcus neoformans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2000, p. 2435 2441 Vol. 44, No. 9 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Interactions between Triazoles
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p Vol. 44, No. 8
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p. 2081 2085 Vol. 44, No. 8 0066-4804/00/$04.00 0 Quantitation of Candida albicans Ergosterol Content Improves the Correlation between In Vitro Antifungal
More informationMurine Pulmonary Aspergillosis
NAOSITE: Nagasaki University's Ac Title Author(s) Citation Efficacy of SPK-843, a Novel Polyen Amphotericin B, Liposomal Amphoteri Murine Pulmonary Aspergillosis Kakeya, Hiroshi; Miyazaki, Yoshitsu Tsutomu;
More informationDivision of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00996.x In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus L. T. Ganesan, E. K.
More informationANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire
ANTIFUNGAL AGENTS Alison Clode, DVM, DACVO Port City Veterinary Referral Hospital Portsmouth, New Hampshire New England Equine Medical and Surgical Center Dover, New Hampshire Overview Fungal organisms
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationFavored by Comments Papers 2375 (rec: 0) Reports Pending Editor:
Favored by Comments Papers 2375 (rec: 0) Reports Pending Editor: Library Search username: password: Register Forgot password Login Register to comment articles, reports and participate in mesh term forums
More informationMINIREVIEW. Combination Antifungal Therapy
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 693 715 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.693 715.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationBiological Consulting Services
Biological Consulting Services of North Florida/ Inc. May 13, 2009 Aphex BioCleanse Systems, Inc. Dear Sirs, We have completed antimicrobial efficacy study on the supplied Multi-Purpose Solution. The testing
More informationSystemic Antifungal Activity of Pyrrolnitrini
PPLIED MICROIOLOGY, May 1969, p. 69-694 Copyright ( 1969 merican Society for Microbiology Vol. 17, No. 5 Printed in U.S.. Systemic ntifungal ctivity of Pyrrolnitrini ROERT S. GORDEE ND THOMS R. MTTHEWS
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationA New Triazole, Voriconazole (UK-109,496), Blocks Sterol Biosynthesis in Candida albicans and Candida krusei
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1997, p. 2492 2496 Vol. 41, No. 11 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology A New Triazole, Voriconazole (UK-109,496), Blocks
More informationPharmacokinetics of Fluconazole in Cerebrospinal Fluid and Serum
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1988, p. 369-373 Vol. 32, No. 3 0066-4804188/030369-05$02.00/0 Copyright 1988, American Society for Microbiology Pharmacokinetics of Fluconazole in Cerebrospinal
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationMode of Action of Miconazole on Candida albicans: Effect on Growth, Viability and K+ Release
Journal of General Microbiology (1980), 119, 245-251. Printed in Great Britain 245 Mode of Action of Miconazole on Candida albicans: Effect on Growth, Viability and K+ Release By JANE E. COPE? University
More informationB. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.
Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationMATERIALS AND METHODS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1999, p. 2841 2847 Vol. 43, No. 12 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Interaction between Fluconazole
More informationComparison of Fluconazole and Amphotericin B for Treatment of Disseminated Candidiasis and Endophthalmitis in Rabbits
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1991, p. 288-292 66-484/91/2288-5$2./ Copyright 1991, American Society for Microbiology Vol. 35, No. 2 Comparison of Fluconazole and Amphotericin B for Treatment
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationActivity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 758 764 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.758 764.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationaureus."' Previous studies from this laboratory have shown that this agent despite the availability of antimicrobial agents that are effective against
RICHARD E. DIXON* Department of Medicine, JAY S. GOODMAN * * George Vanderbilt Hunter University Laboratory, School of Medicine, M. GLENN KOENIG*** Nashville, Tennessee 3723 LYSOSTAPHIN: AN ENZYMATIC APPROACH
More informationEvaluation of Antibacterial Effect of Odor Eliminating Compounds
Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationAntifungal Potential of Disulfiram
Jpn. J. Med. Mycol. Vol. 48, 109 113, 2007 ISSN 0916 4804 Short Report Antifungal Potential of Disulfiram Seema Khan 1, Smita Singhal 1, Tarun Mathur 1, Dilip J. Upadhyay 1, Ashok Rattan 2 1 Department
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationNatural History of Aortic Valve Endocarditis in Rats
INFECTION AND IMMUNITY, JUlY 192, p. 127-131 19-9567/2/7127-5$2./ Vol. 37, No. 1 Natural History of Aortic Valve Endocarditis in Rats ERIC HtRAIEF, MICHEL P. GLAUSER,* AND LAWRENCE R. FREEDMANt Division
More informationInternational Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents 33 (2009) 258 263 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: http://www.elsevier.com/locate/ijantimicag
More informationSusceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B
OnLine Journal of Biological Sciences 10 (2): 109-113, 2010 ISSN 1608-4217 2010 Science Publications Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin
More informationRecipes for Media and Solution Preparation SC-ura/Glucose Agar Dishes (20mL/dish, enough for 8 clones)
Protocol: 300 ml Yeast culture preparation Equipment and Reagents needed: Autoclaved toothpicks Shaker Incubator set at 30 C Incubator set at 30 C 60 mm 2 sterile petri dishes Autoclaved glass test tubes
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationFOR THE USE ONLY OF A REGISTERED MEDICAL PRACTITIONER OR A HOSPITAL OR A LABORATORY Liposomal Amphotericin B Injection I.P. (LyophilIzed) 50mg
FOR THE USE ONLY OF A REGISTERED MEDICAL PRACTITIONER OR A HOSPITAL OR A LABORATORY Liposomal Amphotericin B Injection I.P. AMPHONEX (LyophilIzed) 50mg For Intravenous infusion to hospitalized patients
More informationAerosolized Liposomal Amphotericin B for Treatment of
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1992, p. 1466-1471 66-484/92/71466-6$2./ Copyright X 1992, American Society for Microbiology Vol. 36, No. 7 Aerosolized Liposomal Amphotericin B for Treatment
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationMPO-KO MPO-KO , NADPH. O 2, , MPO-KO 5. HOCl, H 2 O 2., MPO, MPO-KO. HOCl. ., MPO-KO 3., MPO MPO 1, 2. MPO, ., Candida albicans ATCC O 2, MPO-KO
Jpn. J. Med. Mycol. Vol. 47, 195 199, 26 ISSN 916 484 MPO,. MPO MPO-KO,. MPO-KO., C. albicans,, MPO-KO 5., A. fumigatus, C. tropicalis, T. asahii 2,. MPO-KO C. neoformans 7, 3., MPO., MPO-KO C. albicans
More informationFreezing, and Ultraviolet
APPLIED MICROBIOLOGY, May, 1966 Vol. 14, No. 3 Copyright ( 1966 American Society for Microbiology Printed in U.S.A. Effect of Pimaricin on the Resistance of Saccharomyces cerevisiae to Heat, Freezing,
More informationAmphotericin B Serum Concentrations
APPLIED MICROBIOLOGY, June 197, p. 955-959 Copyright 197 American Society for Microbiology Vol. 19, No. 6 Printed in U.S.A. Amphotericin B Serum Concentrations During Therapyt BRANCH T. FIELDS, JR., JOSEPH
More informationRapid detection of lytic antimicrobial activity against yeast and filamentous fungi
Journal of Microbiological Methods 49 (2002) 1 9 www.elsevier.com/locate/jmicmeth Rapid detection of lytic antimicrobial activity against yeast and filamentous fungi Sally N. Jewell 1, Robert H. Waldo
More informationThe effect of farnesol on amino acid incorporation by a wild-type and cell-wall variant strain of Candida albicans
Fairfield University DigitalCommons@Fairfield Biology Faculty Publications Biology Department 1-1-2005 The effect of farnesol on amino acid incorporation by a wild-type and cell-wall variant strain of
More informationEmergence of a New Opportunistic Pathogen, Candida lusitaniae
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1989, p. 236-240 Vol. 27, No. 2 0095-1137/89/020236-05$02.00/0 Copyright ( 1989, American Society for Microbiology Emergence of a New Opportunistic Pathogen, Candida
More informationEfficacy of D0870 Treatment of Experimental Candida Vaginitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1997, p. 1455 1459 Vol. 41, No. 7 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Efficacy of D0870 Treatment of Experimental Candida
More informationFactors Affecting the Resistance of Staphylococcus
APPLIED MICROBIOLOGY, Jan., 1967, p. 97-101 Copyright 1967 American Society for Microbiology Vol. 15, No. 1 Printed in U.S.A. Factors Affecting the Resistance of Staphylococcus aureus to Hydrogen Peroxide
More informationSusceptibilities of Candida spp. to Antifungal Agents Visualized by Two-Dimensional Scatterplots of Relative Growth
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1996, p. 588 594 Vol. 40, No. 3 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Susceptibilities of Candida spp. to Antifungal Agents
More information*Corresponding author: ABSTRACT
Pathology and Hygiene SUSCEPTIBILITY, RESISTANCE AND ANTIBIOTIC PROFILE OF BACITRACIN AGAINST CLOSTRIDIUM PERFRINGENS STRAINS ISOLATED DURING CLINICAL OUTBREAKS OF EPIZOOTIC RABBIT ENTEROPATHY Richez P.
More informationISSN Vol.02,Issue.19, December-2013, Pages:
www.semargroups.org, www.ijsetr.com ISSN 2319-8885 Vol.02,Issue.19, December-2013, Pages:2180-2185 Studies on Antifungal Properties of Some Plant Extracts (Garlic, Fenugreek, Ginger) Against of Clinical
More informationAspirin antagonism in isonizaid treatment of tuberculosis in mice ACCEPTED. Department of Molecular Microbiology & Immunology, Bloomberg School of
AAC Accepts, published online ahead of print on 4 December 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01145-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationLoyola ecommons. Loyola University Chicago. Virginia Long Loyola University Chicago. Recommended Citation
Loyola University Chicago Loyola ecommons Master's Theses Theses and Dissertations 2014 Identification of Clinical Markers That Predict the Outcomes of Methicillin-Resistant Staphylococcus Aureus Infections
More informationAntifungal Properties of Cranberry Juice
APPLIED MICROBIOLOGY, OCt. 1968, p. 1524-1527 Copyright @ 1968 American Society for Microbiology Vol. 16, No. 10 Printed in U.S.A. Antifungal Properties of Cranberry Juice JACOB H. SWARTZ AND THEODORE
More informationPrevalence and Management of Non-albicans Vaginal Candidiasis
Prevalence and Management of Non-albicans Vaginal Candidiasis Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson To cite this version: Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson. Prevalence and Management
More informationPotato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1455 1461 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1455 1461.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationThe activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
Journal of Antimicrobial Chemotherapy (984) 4, Suppl. B, 39-43 The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ANCOTIL 500 mg, tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Flucytosine 500 mg Per tablet. 3. PHARMACEUTICAL FORM Tablet. 4. CLINICAL
More informationAntifungal activity of Histatin-5 against non-albicans Candida species.
Antifungal activity of Histatin-5 against non-albicans Candida species. Abstract Fungicidal effects of Histatin-5 against 26 oral isolates belonging to 5 non-albicans Candida species were examined. Fifty
More informationKYAMC Journal Vol. 2, No.-2, January Bioequivalence study of Flunac and Diflucan in healthy Bangladeshi male volunteers
Original Article Bioequivalence study of Flunac and Diflucan in healthy Bangladeshi male volunteers Sarker UK 1, Misbahuddin M 2, Hossain MA 3. Abstract A bioequivalence study of a local antifungal drug,
More information